This study will test whether patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck benefit from adoptive cell therapy (ACT) using their own tumor infiltrating lymphocytes (TILs).
TILs are a type of immune cell that can fight cancer. Patients will undergo a chemotherapy regimen, and then researchers will extract a tumor sample. The sample will be cultured in the laboratory to increase the number of TILs. Later, patients are reinfused with the autologous TIL (LN-145).
Iovance Biotherapeutics sponsors this study.